Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E43.46 EPS (ttm)9.96 Insider Own0.40% Shs Outstand109.12M Perf Week-2.25%
Market Cap47.25B Forward P/E26.30 EPS next Y16.47 Insider Trans-24.37% Shs Float79.18M Perf Month-0.11%
Income1.15B PEG2.42 EPS next Q3.85 Inst Own71.80% Short Float2.88% Perf Quarter-16.93%
Sales5.24B P/S9.02 EPS this Y39.50% Inst Trans0.14% Short Ratio3.09 Perf Half Y16.41%
Book/sh52.07 P/B8.32 EPS next Y10.19% ROA15.50% Target Price498.26 Perf Year16.63%
Cash/sh11.62 P/C37.27 EPS next 5Y17.96% ROE23.90% 52W Range325.35 - 543.55 Perf YTD17.95%
Dividend- P/FCF48.22 EPS past 5Y38.80% ROI18.20% 52W High-20.34% Beta1.59
Dividend %- Quick Ratio3.40 Sales past 5Y61.30% Gross Margin55.20% 52W Low33.08% ATR10.35
Employees5400 Current Ratio3.80 Sales Q/Q21.20% Oper. Margin32.30% RSI (14)37.69 Volatility1.81% 2.34%
OptionableYes Debt/Eq0.13 EPS Q/Q97.80% Profit Margin22.10% Rel Volume1.34 Prev Close440.94
ShortableYes LT Debt/Eq0.13 EarningsNov 08 BMO Payout0.00% Avg Volume738.95K Price432.98
Recom2.30 SMA20-3.49% SMA50-5.71% SMA2000.56% Volume990,281 Change-1.81%
Oct-20-17Downgrade Barclays Equal Weight → Underweight $450 → $395
Sep-29-17Resumed Piper Jaffray Overweight $540
Sep-15-17Initiated RBC Capital Mkts Sector Perform $475
Sep-06-17Resumed Raymond James Outperform $566
Aug-17-17Initiated Evercore ISI Outperform $605
Aug-04-17Reiterated UBS Buy $489 → $535
Aug-01-17Downgrade Robert W. Baird Neutral → Underperform $408
Jun-30-17Reiterated BTIG Research Buy $480 → $540
Jun-26-17Downgrade Bernstein Outperform → Mkt Perform
Jun-20-17Reiterated Piper Jaffray Overweight $446 → $557
May-05-17Upgrade Canaccord Genuity Hold → Buy $375 → $484
Mar-29-17Reiterated UBS Buy $435 → $446
Mar-17-17Initiated Oppenheimer Perform
Mar-09-17Initiated UBS Buy $435
Feb-16-17Downgrade Goldman Buy → Neutral
Jan-06-17Reiterated RBC Capital Mkts Outperform $626 → $598
Jan-06-17Reiterated Chardan Capital Markets Neutral $350 → $345
Dec-20-16Upgrade Credit Suisse Neutral → Outperform
Dec-12-16Upgrade Chardan Capital Markets Sell → Neutral $300 → $350
Nov-07-16Reiterated Chardan Capital Markets Sell $325 → $300
Oct-20-17 03:57PM  Another Regeneron Bear Is Born Barrons.com
08:47AM  Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling Zacks
Oct-19-17 02:30PM  Science Magazine Ranks Regeneron #1 Biopharma Employer for Fifth Time PR Newswire
08:06AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
Oct-18-17 07:32AM  Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug Zacks
Oct-17-17 12:58PM  Regeneron-Sanofi drug succeeds mid-stage study Reuters
10:48AM  Sanofi/Regeneron's Dupixent Succeeds in Phase II Study Zacks
08:39AM  Gilead Sciences on the Street: Analyst Recommendations in October Market Realist
Oct-16-17 06:16PM  UPDATE 1-Regeneron-Sanofi drug succeeds mid-stage study Reuters
09:19AM  Aimmune teams with Regeneron, Sanofi on peanut allergy drug Reuters
08:17AM  Regeneron-Sanofi throat infection drug succeeds key study Reuters
08:01AM  6 Top Biotech Companies In Innovation Earn Recognition In New Awards Investor's Business Daily
08:00AM  Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis PR Newswire
07:49AM  Regeneron Advances Science To Attack Arthritis, Eye Disease, More Investor's Business Daily
07:42AM  Dupixent May Be Strong Growth Driver for Sanofi in the Future Market Realist
07:20AM  Drugmakers Are Planning to Start a Phase 2 Trial to Cure Peanut Allergy Bloomberg
Oct-12-17 10:31AM  Pres Trump believes he has the cure for Obamacare Yahoo Finance Video
Oct-11-17 05:58PM  Dow's Merck Bails On Cholesterol Drug, Prodding Shares Down Investor's Business Daily
09:30AM  Regeneron to Report Third Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on November 8, 2017 PR Newswire
08:07AM  Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit Zacks
08:00AM  Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis PR Newswire
Oct-10-17 04:57PM  This Biotech Hit Record High; Could Undercut Regeneron In Eczema Investor's Business Daily
Oct-09-17 02:28PM  [$$] Ruling Goes Regeneron's Way Barrons.com
08:15AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : October 9, 2017 Capital Cube
Oct-06-17 05:37PM  Why Regeneron's Patent Win Is Worse For Amgen Than You Think Investor's Business Daily
09:00AM  Regeneron and Sanofi Get Favorable Ruling Against Amgen Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Amgen and Regeneron ACCESSWIRE
Oct-05-17 04:50PM  Regeneron Pops After Judge Tosses Ban On Amgen-Rivaling Med Investor's Business Daily
01:51PM  [$$] Appeals Court Rules Against Amgen in Patent Case The Wall Street Journal
01:14PM  U.S. court reverses ban on sale of Regeneron, Sanofi cholesterol drug Reuters
01:01PM  Regeneron spiking on court ruling vs. Amgen CNBC Videos
12:56PM  Regeneron shares pop on cholesterol drug approval CNBC Videos
12:30PM  Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab) PR Newswire
11:13AM  Why Amgen is Sliding Barrons.com
10:30AM  Why Regeneron Pharmaceuticals Dropped 11.3% in September Motley Fool
10:09AM  U.S. court reverses ban on sales of Sanofi, Regeneron drug Praluent Reuters
Oct-04-17 02:11PM  Analyst Recommendations for Exelixis in October 2017 Market Realist
07:54AM  Biotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira Litigation Zacks
Oct-03-17 04:58PM  Endocyte Inks Deal For Prostate Cancer Candidate, Shares Up Zacks
09:50AM  Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA Zacks
09:30AM  3 Top-Ranked Big Biotech Stocks to Buy Now Zacks
09:24AM  FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta Zacks
Oct-02-17 06:24PM  Novo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults Zacks
06:19PM  Lilly (LLY) Makes Leadership Changes to Executive Positions Zacks
05:59PM  Prothena's Psoriasis Candidate Disappoints in Phase I Study Zacks
07:00AM  Regeneron Announces New Collaborations with HHS to Develop Antibodies Against Ebola, Influenza and Multiple Other Emerging Pathogens PR Newswire
Sep-29-17 12:22PM  Should You Sell Regeneron Pharmaceuticals Inc (REGN) At This PE Ratio? Simply Wall St.
12:20PM  US invests $170 million in late-stage Ebola vaccines, drugs Reuters
Sep-28-17 07:32PM  3 Stocks That Turned $7,000 Into $130,200 Motley Fool
01:02AM  Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union GlobeNewswire
01:01AM  EU approves Sanofi and Regeneron's dupilumab in eczema Reuters
01:00AM  Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union PR Newswire
Sep-27-17 04:03PM  Galapagos Pops After Eczema Drug Shows Promise Vs. Regeneron Investor's Business Daily
Sep-26-17 10:24AM  Infinity/ Bristol-Myers Adds TNBC Patients to Clinical Deal Zacks
Sep-25-17 10:49AM  Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer Zacks
Sep-22-17 11:17AM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : September 22, 2017 Capital Cube
10:41AM  The Medicines Co. Continues to Focus on Pipeline Development Zacks
09:53AM  Bayer (BAYRY) Focuses on Pipeline Development & Acquisitions Zacks
Sep-21-17 11:01AM  Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up Zacks
10:15AM  How is the Age-Related Macular Degeneration Space Faring Now? Zacks
Sep-20-17 02:10PM  ProQR's Genetic Disorder Candidate Gets Orphan Drug Status Zacks
11:22AM  Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017 Capital Cube
10:36AM  Teva/Nuvelution to Speed Up Development of Austedo in US Zacks
08:08AM  What Analysts Recommend for Zoetis and Peers in September 2017 Market Realist
Sep-19-17 02:59PM  [$$] Regeneron's Biggest Long-Term Opportunity Barrons.com
10:37AM  Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia Zacks
10:35AM  Pluristem's Ischemia Candidate Gets Fast Track Designation Zacks
09:19AM  Zacks.com featured highlights include include Hasbro, Regeneron Pharmaceuticals, Applied Materials, Vantiv, and CBRE Group Zacks
Sep-18-17 10:23AM  Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU Zacks
09:07AM  Regeneron Is Focused on Advancing Development of Fasinumab for Chronic Pain Market Realist
07:37AM  Kevzara May Emerge as a Prominent Rheumatoid Arthritis Drug in 2017 Market Realist
Sep-16-17 02:17AM  Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis GlobeNewswire
02:15AM  Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis PR Newswire
Sep-15-17 10:38AM  Label Expansion in Asthma Indication May Boost Dupixents Sales Market Realist
09:10AM  Regulatory Approval in Asthma Indication May Boost Dupixents Sales Market Realist
07:38AM  Dupixent Expected to Become a Leading Therapy for Atopic Dermatitis Market Realist
Sep-14-17 11:25AM  Glaxo's Shingles Candidate Gets Positive FDA Committee Vote Zacks
11:05AM  Alexion (ALXN) Reports Interim Results for Soliris Study Zacks
10:39AM  Eylea Leads the Retinal Diseases Sector Market Realist
09:36AM  Regeneron Is Focused on Increasing Awareness for Eylea in 2017 Market Realist
08:09AM  Analysts Recommendations for Regeneron in September 2017 Market Realist
Sep-13-17 06:02PM  Alexion to Restructure Operations, to Lower Headcount by 20% Zacks
08:33AM  Biotech Stock Roundup: Alexion to Cut Jobs, Streamline Operations, Kura Up on Cancer Data Zacks
07:16AM  Regeneron's Dupixent Takes Another Step Toward Blockbuster Status Motley Fool
Sep-12-17 01:26PM  Sanofi indicates dupilumab could be used to treat nasal polyps Reuters
11:25AM  AstraZeneca's Asthma Candidate Shows Promising Results Zacks
08:53AM  Regeneron's Delivery Isn't Matching the Hype Bloomberg
06:48AM  5 Things Regeneron's CEO Said as the Biotech Stock Sank Motley Fool
Sep-11-17 07:30PM  5 Ways To Play The Biotech Bull Market Oilprice.com -5.60%
04:30PM  Federated, Carnival, Alphabet climb; Regeneron skids Associated Press
04:30PM  Why Equifax, Regeneron Pharmaceuticals, and AngloGold Ashanti Slumped Today Motley Fool
04:22PM  Here's Why Regeneron Toppled Despite A Successful Drug Trial Investor's Business Daily
03:30PM  Regeneron: When Good Isn't Good Enough Barrons.com
03:17PM  AstraZeneca's Lung Cancer Study Data Promising, Shares Spike Zacks
02:15PM  Regeneron/Sanofi's Dupixent Asthma Study Meets Endpoints Zacks
01:08PM  Regeneron, Sanofi asthma drug data fails to excite investors Reuters
10:58AM  Top Ranked Momentum Stocks to Buy for September 11th Zacks
09:33AM  5 Top-Ranked Biotech Stocks to Buy Right Now Zacks
07:25AM  Featured Company News - Regeneron Pharma and Sanofi's Cemiplimab Receives Breakthrough Therapy Designation from US FDA ACCESSWIRE
01:14AM  Sanofi and Regeneron announce positive dupilumab topline results Reuters
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children's. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; and the U.S. Department of Health and Human Services to develop treatments combating infectious diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BROWN MICHAEL SDirectorOct 05Option Exercise177.821,500266,7301,500Oct 05 04:18 PM
BROWN MICHAEL SDirectorOct 05Sale475.001,500712,5000Oct 05 04:18 PM
BAKER CHARLES ADirectorSep 29Option Exercise18.612,00037,22011,000Oct 03 04:00 PM
BAKER CHARLES ADirectorSep 29Sale450.002,000900,0009,000Oct 03 04:00 PM
Landry Robert ESVP Finance & CFOSep 06Sale497.62474235,8737,099Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOSep 05Sale501.0618994,7007,573Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOSep 01Option Exercise272.703,000818,10010,099Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOAug 31Sale493.43427210,6937,099Sep 01 04:04 PM
Landry Robert ESVP Finance & CFOAug 30Option Exercise272.702,000545,4009,099Sep 01 04:04 PM
Landry Robert ESVP Finance & CFOAug 23Sale476.45468222,9817,099Aug 24 04:47 PM
Landry Robert ESVP Finance & CFOAug 22Option Exercise272.702,000545,4009,099Aug 24 04:47 PM
VAGELOS P ROYChairman of the BoardAug 22Sale477.6431,94415,257,816329,543Aug 23 04:21 PM
VAGELOS P ROYChairman of the BoardAug 21Sale470.3224,26911,414,076361,487Aug 23 04:21 PM
VAGELOS P ROYChairman of the BoardAug 18Sale470.152,9001,363,435385,756Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 17Sale470.001,305613,350388,656Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 16Option Exercise21.92153,9693,375,000483,512Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 16Sale470.1710,9865,165,288389,961Aug 18 05:00 PM
Terifay Robert JEVP CommercialAug 10Option Exercise52.031,92199,95025,214Aug 11 04:02 PM
Landry Robert ESVP Finance & CFOAug 08Sale472.19526248,3727,099Aug 09 04:03 PM
Landry Robert ESVP Finance & CFOAug 07Option Exercise272.702,000545,4009,099Aug 09 04:03 PM
STAHL NEILEVP Research and DevelopmentJun 22Sale532.558,3064,423,33223,950Jun 23 04:09 PM
Aberman Michael SSVP Strategy Investor RelationJun 22Sale532.422,2691,208,0614,693Jun 23 04:10 PM
Aberman Michael SSVP Strategy Investor RelationJun 21Option Exercise30.634,500137,8359,193Jun 23 04:10 PM
STAHL NEILEVP Research and DevelopmentJun 21Option Exercise30.6320,000612,60043,950Jun 23 04:09 PM
BROWN MICHAEL SDirectorJun 20Option Exercise177.823,000533,4603,000Jun 21 04:11 PM
GOLDSTEIN JOSEPH LDirectorJun 20Option Exercise273.671,000273,67014,000Jun 21 04:12 PM
BROWN MICHAEL SDirectorJun 20Sale500.003,0001,500,0000Jun 21 04:11 PM
GOLDSTEIN JOSEPH LDirectorJun 20Sale500.011,000500,01013,000Jun 21 04:12 PM
Terifay Robert JEVP CommercialJun 16Sale468.1921,1479,900,81423,293Jun 19 04:44 PM
Terifay Robert JEVP CommercialJun 15Option Exercise52.0348,7502,536,46372,043Jun 19 04:44 PM
STAHL NEILEVP Research and DevelopmentJun 15Sale468.458,5674,013,17723,950Jun 16 04:36 PM
STAHL NEILEVP Research and DevelopmentJun 14Option Exercise21.2520,295431,26944,245Jun 16 04:36 PM
BROWN MICHAEL SDirectorJun 12Option Exercise177.822,000355,6402,000Jun 14 04:36 PM
BROWN MICHAEL SDirectorJun 12Sale474.452,000948,8900Jun 14 04:36 PM
GOLDSTEIN JOSEPH LDirectorJun 09Option Exercise273.671,000273,67014,000Jun 13 05:06 PM
GOLDSTEIN JOSEPH LDirectorJun 09Sale482.551,000482,55013,000Jun 13 05:06 PM
STAHL NEILEVP Research and DevelopmentJun 02Sale479.492,8121,348,31423,950Jun 05 04:52 PM
STAHL NEILEVP Research and DevelopmentJun 01Option Exercise198.3810,5442,091,72430,814Jun 05 04:52 PM
VAGELOS P ROYChairman of the BoardMay 25Sale458.149,2954,258,37383,652May 26 04:04 PM
BROWN MICHAEL SDirectorMay 12Option Exercise177.823,000533,4603,000May 15 04:07 PM
BROWN MICHAEL SDirectorMay 12Sale450.003,0001,350,0000May 15 04:07 PM
BROWN MICHAEL SDirectorMar 29Option Exercise177.821,000177,8201,000Mar 30 04:42 PM
BROWN MICHAEL SDirectorMar 29Sale400.001,000400,0000Mar 30 04:42 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 15Option Exercise20.32195,0793,964,005697,000Dec 19 04:09 PM
SCHLEIFER LEONARD SPresident & CEODec 15Option Exercise20.32250,0005,080,000292,806Dec 19 04:07 PM
BAKER CHARLES ADirectorDec 12Option Exercise18.613,00055,83012,000Dec 14 05:41 PM
BAKER CHARLES ADirectorDec 12Sale392.023,0001,176,0489,000Dec 14 05:41 PM
RYAN ARTHUR FDirectorNov 15Sale429.342,000858,68036,500Nov 16 04:21 PM
GOLDSTEIN JOSEPH LDirectorNov 14Option Exercise273.672,125581,54915,125Nov 15 04:08 PM
GOLDSTEIN JOSEPH LDirectorNov 14Sale450.002,125956,25013,000Nov 15 04:08 PM
VAGELOS P ROYChairman of the BoardNov 07Option Exercise20.3276,8951,562,506515,726Nov 09 04:10 PM